0.00Open0.00Pre Close0 Volume0 Open Interest11.50Strike Price0.00Turnover781.08%IV-51.92%PremiumDec 13, 2024Expiry Date3.93Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6989Delta0.0866Gamma1.67Leverage Ratio-0.4316Theta-0.0004Rho-1.17Eff Leverage0.0018Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class Cdk7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability
No comment yet